Communiqués Roche Holding AG Swiss Exchange

Actions

RO

CH0012032113

Produits pharmaceutiques

Marché Fermé - Swiss Exchange 17:30:53 24/09/2026			Varia. 5j.	Varia. 1 janv.
376,40 ^CHF	+0,32%		+2,12%	+12,29%

24/09	Bourse Zurich: le SMI clôture dans le rouge, plombé par le pétrole	AW
24/09	Atavistik Bio, Inc. et Roche annoncent une collaboration stratégique de recherche pour découvrir et développer de nouveaux traitements allostériques	CI

Communiqués

23/09	Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)	BU
22/09	Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity	BU
17/09	Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center	BU
17/09	Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study	BU
10/09	U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments	BU
20/08	Genentech Announces Manufacturing Expansion in Hillsboro, Oregon	BU
18/08	Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility	BU
20/07	Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America	PR
15/07	FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy	BU
07/07	Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC	BU
02/07	Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer	BU
30/06	FDA grants Priority Review to Roche's Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)	AQ
30/06	FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)	BU
18/06	FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma	BU
11/06	FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer	BU
04/06	Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection	PR
02/06	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	BU
01/06	Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions	BU
19/05	Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer	BU
15/05	FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment	BU
30/04	Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026	BU
24/04	Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign	BU
22/04	Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD	AQ
22/04	Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS	BU
21/04	Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD	BU